| Literature DB >> 35854357 |
Fiona Murphy1, Nicklas Raun Jacobsen2, Emilio Di Ianni2, Helinor Johnston3, Hedwig Braakhuis4, Willie Peijnenburg4,5, Agnes Oomen4, Teresa Fernandes3, Vicki Stone3.
Abstract
BACKGROUND: The EU-project GRACIOUS developed an Integrated Approach to Testing and Assessment (IATA) to support grouping high aspect ratio nanomaterials (HARNs) presenting a similar inhalation hazard. Application of grouping reduces the need to assess toxicity on a case-by-case basis and supports read-across of hazard data from substances that have the data required for risk assessment (source) to those that lack such data (target). The HARN IATA, based on the fibre paradigm for pathogenic fibres, facilitates structured data gathering to propose groups of similar HARN and to support read-across by prompting users to address relevant questions regarding HARN morphology, biopersistence and inflammatory potential. The IATA is structured in tiers, allowing grouping decisions to be made using simple in vitro or in silico methods in Tier1 progressing to in vivo approaches at the highest Tier3. Here we present a case-study testing the applicability of GRACIOUS IATA to form an evidence-based group of multiwalled carbon nanotubes (MWCNT) posing a similar predicted fibre-hazard, to support read-across and reduce the burden of toxicity testing.Entities:
Keywords: Grouping; High aspect ratio nanomaterials; Read-across
Mesh:
Substances:
Year: 2022 PMID: 35854357 PMCID: PMC9297605 DOI: 10.1186/s12989-022-00487-6
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.112
Gracious pre-defined hypotheses for inhalation route of exposure
| Hypothesis title | Reference |
|---|---|
| Respirable NFs with an instantaneous dissolution rate: Following inhalation exposure, the toxicity is driven by and is therefore similar to those of the constituent ions or molecules | [ |
| Respirable NFs with a quick dissolution rate: Following inhalation exposure both NFs and constituent ions or molecules may contribute to toxicity, but there is no concern for accumulation. Toxicity (also) depends on the location of the ionic or molecular release | [ |
| Respirable NFs with a gradual dissolution rate: Following inhalation exposure both NFs and constituent ions or molecules may contribute to toxicity and there is some concern for accumulation. Toxicity (also) depends on the location of the ionic or molecular release | [ |
| Respirable NFs with a very slow dissolution rate: Following inhalation exposure, toxicity is driven by the NFs and accumulation of NFs in the lungs can lead to long-term toxicity | [ |
| Respirable, biopersistent, rigid HARN: Following inhalation exposure, long-term pulmonary retention of HARN can occur resulting in lung toxicity | [ |
| Respirable, biopersistent, rigid HARN: Following inhalation exposure and translocation of HARN to the pleura, mesothelioma development can occur | [ |
Panel of MWCNT included in case study
| Carbon (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (µm) | ± SD (µm) | Mean (nm) | ± SD (nm) | (m2/g) | mmol/g | ||||||
| NM-400 | JRC | JRCNM04000a | PRISTINE | 86.2 | 0.85 | 0.1 | 11 | 3 | 77.27 | 254 | 0.79 |
| NM-401 | JRC | JRCNM04001a | PRISTINE | 99.7 | 4 | 0.37 | 67 | 24 | 59.7 | 18 | 0.03 |
| NM-402 | JRC | JRCNM04002a | PRISTINE | 96.1 | 1.4 | 0.19 | 11 | 3 | 127.27 | 226 | 0.28 |
| NM-403 | JRC | JRCNM04003a | PRISTINE | 99.1 | 0.4 | 0.03 | 12 | 7 | 33.33 | 135 | 0.19 |
| NRCWE006 | Mitsui/Hadogaya | XNRI MWNT-7 | PRISTINE | 99.6 | 5.7 | 0.49 | 74 | 77.02 | 26 | 0.08 | |
| NRCWE040 | Cheaptubes | sku-030102 | PRISTINE | 98.6 | 0.52 | 0.59 | 20.56 | 6.9 | 25.29 | 150 | 0.35 |
| NRCWE041 | Cheaptubes | sku-030202 | OH | 99.2 | 1 | 2.95 | 26.38 | 11.1 | 37.9 | 152 | 1.69 |
| NRCWE042 | Cheaptubes | sku 030,302 | COOH | 99.2 | 0.72 | 0.97 | 20.5 | 5.32 | 35.12 | 141 | 4.09 |
| NRCWE043 | Cheaptubes | sku 030,107 | PRISTINE | 96 | 0.771 | 3.471 | 26.73 | 6.88 | 28.84 | 82 | 0.18 |
| NRCWE044 | Cheaptubes | sku 030,207 | OH | 96 | 1.33 | 2.454 | 32.55 | 14.4 | 40.92 | 74 | 0.23 |
| NRCWE045 | Cheaptubes | Sku 030,307 | COOH | 92 | 1.553 | 2.954 | 28.07 | 13.85 | 55.32 | 119 | 0.63 |
| NRCWE046 | Cheaptubes | sku-030111 | PRISTINE | 98.7 | 0.72 | 1.2 | 17.2 | 5.8 | 41.8 | 223 | 0.63 |
| NRCWE047 | Cheaptubes | sku 030,112 | OH | 98.7 | 0.53 | 0.59 | 12.96 | 4.4 | 40.89 | 216 | 0.26 |
| NRCWE048 | Cheaptubes | sku030113 | COOH | 98.8 | 1.6 | 5.6 | 15.08 | 4.7 | 106.1 | 185 | 0.58 |
| NRCWE049 | Cheaptubes | sku 030,114 | NH2 | 96 | 0.731 | 1.473 | 13.85 | 6.09 | 52.77 | 199 | 0.33 |
PC characterisation data extracted from [11, 13]. Surface area determined by Brunauer–Emmett–Teller (BET) surface area analysis, Carbon purity and oxygen content determined by combustion elemental analysis, length and diameter measured by scanning electron microscopy of MWCNT dispersed by ultrasonication in media containing 2% fetal calf serum
Fig. 1Integrated Approach to Testing and Assessment (IATA) to test the GRACIOUS pre-defined grouping hypothesis: Respirable, biopersistent, rigid HARN: Following inhalation exposure, long-term pulmonary retention of HARN can occur resulting in lung toxicity.
Adapted from [7]
Tiered Testing Strategy to support the HARN IATA. Recommended methods and models to address each IATA decision node are set-out according to the appropriate tier of testing.
Adapted from [7]
| Can HARN deposit in the distal lung? | Does the HARN dissolve very slowly in lung lining fluid (pH7.4)? | Does the HARN dissolve very slowly in lysosomal fluid (pH4.5)? | Is HARN length > 5 µm? | Is HARN rigid and maintain a needle-like morphology? | Does HARN cause frustrated phagocytosis? |
|---|---|---|---|---|---|
| Tier 1 | |||||
| Review existing data sets | |||||
| Estimation of aerodynamic diameter from diameter and density of HARN | Batch dissolution test or dissolution in continuous flow system in lung lining fluid | Batch dissolution test or dissolution in continuous flow system in lysosomal fluid | Length distribution profile from TEM/SEM images | Mean diameter of HARN from TEM/SEM. Include supporting images | Inflammasome activation in macrophage exposed to HARN: IL-1β release |
| Tier 2 | |||||
| Review existing data sets | |||||
| Measurement of mass median aerodynamic diameter (MMAD) from airborne dispersion of material | Durability in cellular systems | HARN length measurement from airborne dispersion of material from TEM/SEM images | HARN size measurement from airborne dispersion of material from TEM/SEM images. Include supporting images | In vitro granuloma formation | |
| Tier 3 | |||||
| Review existing data sets | |||||
| Quantification of lung deposition during in vivo inhalation studies | Quantification of lung burden and clearance kinetics during in vivo inhalation studies | Fibre rigidity of HARN demonstrated by morphological assessment and/or size measurements after incubation with macrophages in vitro or in vivo | Evidence of frustrated phagocytosis and granuloma formation from in vivo exposure (OECD GD 39) | ||
Overview of the data availability for the MWCNT panel from the data set extracted from the NRCWE studies for each IATA decision node and Tier of the tiered testing strategy
| Can HARN deposit in the distal lung? | Does the HARN dissolve very slowly in lung lining and/or lysosomal fluid? | Is HARN length > 5 µm? | Is the HARN rigid and maintain a fibrous, needle-like morphology? | Does the HARN cause frustrated phagocytosis? | |
|---|---|---|---|---|---|
| Tier 1 | Estimated Dae based on mean diameter and assumed density of not appropriate for heterogenous HARN | No data from in vitro dissolution studies. MWCNT predicted to be durability based on graphene structure | Size distribution profiles not available. Mean length reported | Diameter of primary particle reported plus supporting SEM images where available | Frustrated phagocytosis not specifically addressed |
| Tier 2 | Measured MMAD not reported | No data from intracellular dissolution studies | Size distribution of aerosolized MWCNT not reported | Size distribution of aerosolized MWCNT not reported | No data from 3D granuloma model |
| Tier 3 | Deposition after inhalation exposure not reported | Qualitative evidence of biopersistence in lung was available | Qualitative evidence of fibre rigidity for NM-401 and NRCWE006 in BAL macrophages and lung and liver tissue was available | Qualitative evidence of frustrated phagocytosis of NM-401 and NRCWE006 in BAL macrophages was available |
Please note that this is not a summary of all data for all HARN publications available to date, only those relevant to this case study
Summary of IATA results for MWCNT panel according to each IATA decision node and data available from NRWCE studies at each tier of testing
Yellow box: Decision node outcome is uncertain due to gaps or limited confidence in available data, Grey box: No relevant data available, Green box: Yes to decision node question, Red: No to decision node question
IATA outcome for NM-401 and NRCWE006 after integration of additional decision node information gathered from targeted literature search
| Deposition in distal lung | Does the NF dissolve very slowly in lung lining fluid/lysosomal? | Is HARN length > 5 µm? | Is the HARN rigid and maintain a fibrous, needle-like morphology? | Does the NF cause frustrated phagocytosis? | IATA outcome | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | Tier 2 | Tier 3 | Tier 1 | Tier 2 | Tier 3 | Tier 1 | Tier 2 | Tier 1 | Tier 2 | Tier 3 | Tier 1 | Tier 2 | Tier 3 | ||
| NM-401 | Uncertain | Yes | Yes | Yes (predicted) | No data | Yes | No data | Yes | Yes | No data | Yes | Yes | No data | Yes | Accept grouping hypothesis |
| NRCWE006 | Uncertain | Yes | Yes | Yes (predicted) | No data | Yes | Yes | Yes | Yes | No data | Yes | Yes | Yes | Yes | Accept grouping hypothesis |
Fig. 2IL-1β release from differentiated THP-1 cells exposed to source (NRCWE006) and target (NM-401) MWCNT for 24 h measured by ELISA (n = 3). NRCWE040, NRCWE041, NRCWE042, NRCWE043, NRCWE045, NRCWE046 and NRCWE048 are included for comparison with MWCNT which are not included in the group
Fig. 3Guidance on how to progress to similarity assessment after initial grouping according to the pre-defined HARN hypothesis is accepted
Similarity assessment between source (NRCWE006) and target (NM-401) MWCNTs as well as two MWCNTs for which the original grouping hypothesis was rejected
These two MWCNTs were used to assess the level of similarity required to support grouping and read-across (NM-403, NRCWE040) MWCNT. Data matrix tables were constructed and populated with relevant data from the literature to conduct the pairwise similarity assessment including basic PC characterisation, the endpoints specified by the IATA and hazard assessment endpoints related to reactivity, inflammation and genotoxicity. *For composition: impurities where the contaminant was below the level of detection for the source NRCWE006, the measured value for each target MWCNT is included (% wt, Additional File 8, Table S6).Green box: fold-difference < 2, MWCNT considered similar, yellow box: fold-difference > 2, judgement of similarity requires further consideration, red box: fold-difference > 2 MWCNT considered not similar
Fig. 4Reactive oxygen species (ROS) generation by source (NRCWE006) and target (NM-401, NM-403, NRCWE040) MWCNT measured by DCFH probe (n = 3)